PT - JOURNAL ARTICLE AU - Fournier-Tombs, Eleonore AU - Diouf, Massamba AU - Maiga, Abdine AU - Faye, Sylvain AU - Ndoye, Tidiane AU - Haidara, Lalla AU - Batchily, Moussa AU - Castet-Renard, Céline TI - Covid-19 vaccine perceptions in Senegal and in Mali: a mixed approach AID - 10.1101/2021.10.06.21264664 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.06.21264664 4099 - http://medrxiv.org/content/early/2021/10/07/2021.10.06.21264664.short 4100 - http://medrxiv.org/content/early/2021/10/07/2021.10.06.21264664.full AB - This paper presents the results of two qualitative surveys in Senegal and in Mali, which include questions about hesitancy to the COVID-19 vaccine between April and June 2021. It took place within a larger 2-year research project involving researchers in Senegal, Mali and Canada which examines the uses of artificial intelligence technologies in the fight against COVID-19. The study involved 1000 respondents in Senegal and 555 in Mali. The researchers found that overall, 55% of respondents in Senegal and 52% of respondents in Mali did not plan to be vaccinated. Hesitancy was much higher in youth aged 15-35 in both cases, with 70% of youth in Senegal and 57% of youth in Mali not planning to be vaccinated, compared to only 42% of elderly in Senegal and 37% of elderly in Mali. The researchers did not find disparities between male and female respondents in Senegal but found some in Mali. They also found that those who had a member of the family with chronic disease (diabetes or hypertension) were slightly more likely to want to be vaccinated. Reasons for vaccine hesitancy fell in several categories, including fear of vaccine side-effects, disbelief in vaccine efficacy or usefulness, and general distrust in the public health system.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by the International Development Research Centre (IDRC) in Canada.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics for this research were approved by CNERS Senegal under the title: Protocole SEN20/91: "Usage de l'IA dans la lutter contre le COVID-19"I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data for this research is available for academic purposes upon request.